Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Announcement & Circular
Stock Information
02186.HK
2.66 -0.03  (-1.12%)
Volume：7,626,500
04-20
2026
VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLED IN THE U.S. PK BRIDGING CLINICAL TRIAL OF THE GROUP'S INNOVATIVE DRUG LY03015 (VMAT2 INHIBITOR/SIGMA-1R AGONIST)
Publisher：
04-15
2026
VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLED IN THE CHINA PHASE II CLINICAL TRIAL OF THE GROUP'S INNOVATIVE DRUG LY03017 FOR TREATING ALZHEIMER'S DISEASE-RELATED PSYCHOSIS
Publisher：
04-08
2026
VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLED IN THE PHASE II CLINICAL TRIAL IN CHINA OF THE GROUP'S INNOVATIVE DRUG LY03020
Publisher：
04-08
2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
Publisher：
03-31
2026
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025
Publisher：
03-17
2026
NOTICE OF BOARD MEETING
Publisher：
03-05
2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2026
Publisher：
02-05
2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2026
Publisher：
01-27
2026
DISCLOSEABLE AND CONNECTED TRANSACTION CAPITAL INJECTION IN NANJING LUYE
Publisher：
01-27
2026
DISCLOSEABLE TRANSACTIONS AND CONNECTED TRANSACTION FURTHER ANNOUNCEMENT ON THE TRANSFER OF 25% INTEREST IN NANJING LUYE AND RELATED TRANSACTIONS - COMPLETION OF THE EQUITY ...
Publisher：
First
1
2
3
4
5
Last
Investors
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Stock Information
02186.HK
Volume：7,626,500
2.66
-0.03  (-1.12%)
Announcement & Circular
04-20
2026
VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLED IN THE U.S. PK BRIDGING CLINICAL TRIAL OF THE GROUP'S INNOVATIVE DRUG LY03015 (VMAT2 INHIBITOR/SIGMA-1R AGONIST)
04-15
2026
VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLED IN THE CHINA PHASE II CLINICAL TRIAL OF THE GROUP'S INNOVATIVE DRUG LY03017 FOR TREATING ALZHEIMER'S DISEASE-RELATED PSYCHOSIS
04-08
2026
VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLED IN THE PHASE II CLINICAL TRIAL IN CHINA OF THE GROUP'S INNOVATIVE DRUG LY03020
04-08
2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
03-31
2026
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025
03-17
2026
NOTICE OF BOARD MEETING
03-05
2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2026
02-05
2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2026
01-27
2026
DISCLOSEABLE AND CONNECTED TRANSACTION CAPITAL INJECTION IN NANJING LUYE
01-27
2026
DISCLOSEABLE TRANSACTIONS AND CONNECTED TRANSACTION FURTHER ANNOUNCEMENT ON THE TRANSFER OF 25% INTEREST IN NANJING LUYE AND RELATED TRANSACTIONS - COMPLETION OF THE EQUITY TRANSFER
First
1
2
3
4
5
Last